Published in Lancet on June 27, 1981
Penetration of guinea pig skin by acyclovir in different vehicles and correlation with the efficacy of topical therapy of experimental cutaneous herpes simplex virus infection. Antimicrob Agents Chemother (1984) 1.37
Treatment of erythema multiforme secondary to herpes simplex by prophylactic topical acyclovir. Br Med J (Clin Res Ed) (1981) 1.30
Acyclovir prophylaxis for herpes simplex virus infection. Antimicrob Agents Chemother (1987) 1.08
Alpha interferon and acyclovir treatment of herpes simplex virus in lymphoid cell cultures. Antimicrob Agents Chemother (1982) 0.84
Detection of herpes simplex virus by a nonradiometric spin-amplified in situ hybridization assay. J Clin Microbiol (1992) 0.75
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med (1996) 7.60
Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med (1996) 5.35
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med (1996) 4.43
Recombinant interferon-gamma increases HLA-DR synthesis and expression. J Immunol (1983) 4.09
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med (1996) 4.03
Rapid detection and quantitation of human cytomegalovirus in urine through DNA hybridization. N Engl J Med (1983) 3.83
Interferon: protection of cells infected with an intracellular protozoan (Toxoplasma gondii). Science (1968) 3.65
Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med (1998) 3.55
The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med (1996) 3.35
Inhibition of human immunodeficiency virus gene amplification by heparin. J Clin Microbiol (1991) 3.32
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21
Concerning the mechanism of action of interferon. Proc Natl Acad Sci U S A (1966) 3.15
Inhibition of respiratory virus infection by locally applied interferon. Lancet (1973) 3.02
Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol (1999) 2.89
A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest (1998) 2.88
On-line computer quality control of antibiotic-sensitivity testing. N Engl J Med (1970) 2.88
Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. J Infect Dis (1991) 2.86
Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med (1976) 2.80
Inhibition of TRIC agents by virus-induced interferon. Proc Soc Exp Biol Med (1966) 2.78
Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med (1989) 2.77
Lymphocyte interferon production and transformation after Herpes simplex infections in humans. J Immunol (1974) 2.64
Primary lateral sclerosis. A clinical diagnosis reemerges. Arch Neurol (1988) 2.62
Physical properties of human interferon prepared in vitro and in vivo. Virology (1966) 2.62
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiol (2001) 2.45
Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med (1990) 2.40
HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med (1999) 2.36
Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus. Proc Natl Acad Sci U S A (1984) 2.32
Virus-specific IgG and IgM antibodies in normal and immunocompromised subjects infected with cytomegalovirus. J Infect Dis (1982) 2.29
Evolution of recurrent herpes simplex lesions. An immunohistologic study. J Clin Invest (1985) 2.28
A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis (1993) 2.28
Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis (1997) 2.18
Interferon inducers in vitro: difference in sensitivity to inhbitiros of RNA and protein synthesis. Science (1968) 2.16
Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage. Virology (1988) 2.14
Cellular immunity and herpesvirus infections in cardiac-transplant patients. N Engl J Med (1977) 2.09
Characteristics of immune interferon produced by human lymphocyte cultures compared to other human interferons. J Immunol (1975) 2.09
Measles in adults. An unforeseen consequence of immunization? JAMA (1976) 2.08
Patient compliance and drug failure in protease inhibitor monotherapy. JAMA (1996) 2.06
Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. N Engl J Med (1978) 2.04
Interferon-stimulating and in vivo antiviral effects of various synthetic anionic polymers. Virology (1968) 1.96
Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. J Clin Microbiol (1993) 1.94
Synthetic polyanions protect mice against intracellular bacterial infection. Nature (1970) 1.92
Induction of circulating interferon by synthetic anionic polymers of known composition. Nature (1967) 1.92
Interferon and cytomegalovirus in vivo and in vitro. Proc Soc Exp Biol Med (1967) 1.85
Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. J Clin Invest (1991) 1.85
Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J Infect Dis (1995) 1.79
Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis. J Infect Dis (1995) 1.77
The interaction of human macrophages and lymphocytes in the phytohemagglutinin-stimulated production of interferon. J Clin Invest (1971) 1.75
PPD-stimulated interferon: in vitro macrophage-lymphocyte interaction in the production of a mediator of cellular immunity. Cell Immunol (1971) 1.75
Comparison of QIAamp HCV kit spin columns, silica beads, and phenol-chloroform for recovering human immunodeficiency virus type 1 RNA from plasma. J Clin Microbiol (1997) 1.74
Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial. N Engl J Med (1973) 1.73
A useful quantitative semimicromethod for viral plaque assay. Proc Soc Exp Biol Med (1973) 1.73
Selective increase in lymphocyte interferon response to vaccinia antigen after revaccination. Proc Natl Acad Sci U S A (1972) 1.73
Viral polypeptides detected by a complement-dependent neutralizing murine monoclonal antibody to human cytomegalovirus. J Virol (1985) 1.73
Viral infections in man associated with acquired immunological deficiency states. Fed Proc (1972) 1.70
Human cytomegalovirus (CMV) DNA in plasma reflects quantity of CMV DNA present in leukocytes. J Clin Microbiol (1995) 1.69
An artificial intelligence program to advise physicians regarding antimicrobial therapy. Comput Biomed Res (1973) 1.69
Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS (1999) 1.68
Lymphocyte transformation and interferon production in human mononuclear cell microcultures for assay of cellular immunity to herpes simplex virus. Infect Immun (1976) 1.67
Interferon, antibody, and other host factors in herpes zoster. J Clin Invest (1972) 1.64
The immunosuppressive effect of type II mouse interferon preparations on antibody production. Cell Immunol (1977) 1.64
Is staging beneficial for Fowler-Stephens orchiopexy? A systematic review. J Urol (2010) 1.60
Recombinant gamma interferon induces HLA-DR expression on cultured human keratinocytes. J Invest Dermatol (1984) 1.60
Suppressive effect of interferon on the humoral immune response to sheep red blood cells in mice. J Immunol (1974) 1.60
Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology (1999) 1.59
Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med (1984) 1.58
Bis-DEAE-fluorenone: mechanism of antiviral protection and stimulation of interferon production in the mouse. J Infect Dis (1971) 1.56
Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir. Antimicrob Agents Chemother (1995) 1.55
Herpes Zoster-Varicella infections and lymphoma. Ann Intern Med (1972) 1.54
Current concepts of interferon and interferon induction. Annu Rev Med (1970) 1.53
Preferential accessibility of the yeast his3 promoter is determined by a general property of the DNA sequence, not by specific elements. Mol Cell Biol (2000) 1.53
Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation (1999) 1.52
Patient and allograft survival of Indo Asian and East Asian dialysis patients treated in Canada. Kidney Int (2007) 1.51
Cell-mediated immunity of cytomegalovirus infection in normal subjects and cardiac transplant patients. J Infect Dis (1978) 1.51
Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology (1981) 1.49
Immune specific production of interferon by human T cells in combined macrophage-lymphocyte cultures in response to Herpes simplex antigen. J Immunol (1975) 1.49
The human cytomegalovirus strain Towne glycoprotein H gene encodes glycoprotein p86. Virology (1989) 1.49
Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. J Virol (1997) 1.48
Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual. J Virol (1995) 1.48
Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. J Clin Invest (1980) 1.48
Hereditary occurrence of cystic disease of the renal medulla. N Engl J Med (1966) 1.46
HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients. J Acquir Immune Defic Syndr (1994) 1.44
Diagnosis of cytomegalovirus pneumonia in compromised hosts. Am J Med (1976) 1.44
Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. N Engl J Med (1978) 1.44
Time and dosage dependence of immunoenhancement by murine type II interferon preparations. Cell Immunol (1978) 1.43
Requirement of a stable secondary structure for the antiviral activity of polynucleotides. Nature (1969) 1.43
Detection of human immunodeficiency virus DNA and RNA in semen by the polymerase chain reaction. J Infect Dis (1991) 1.43
Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer. JAMA (1982) 1.42
Increased pulmonary superinfections in cardiac-transplant patients undergoing primary cytomegalovirus infection. N Engl J Med (1978) 1.42
Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother (1997) 1.42
Treatment of NZB/NZW F1 hybrid mice with Mycobacterium bovis strain BCG or type II interferon preparations accelerates autoimmune disease. Arthritis Rheum (1981) 1.41
Cell-mediated immunity to varicella-zoster virus: in vitro lymphocyte responses. J Infect Dis (1974) 1.40
Selective impairment of lymphocyte reactivity to varicella-zoster virus antigen among untreated patients with lymphoma. J Infect Dis (1978) 1.40
Resistance to virus challenge in mice infected with protozoa or bacteria. Proc Soc Exp Biol Med (1969) 1.40
Cytomegalovirus retinitis in immunosuppressed hosts. II. Ocular manifestations. Ann Intern Med (1980) 1.39
Toxicity of vidarabine. JAMA (1979) 1.39